MEP88208A - Leptomycin derivatives - Google Patents

Leptomycin derivatives

Info

Publication number
MEP88208A
MEP88208A MEP-882/08A MEP88208A MEP88208A ME P88208 A MEP88208 A ME P88208A ME P88208 A MEP88208 A ME P88208A ME P88208 A MEP88208 A ME P88208A
Authority
ME
Montenegro
Prior art keywords
leptomycin derivatives
conjugates
leptomycin
derivatives
therapeutic use
Prior art date
Application number
MEP-882/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Herve Bouchard
Alain Commercon
Ravi V J Chari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37311892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP88208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of MEP88208A publication Critical patent/MEP88208A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MEP-882/08A 2006-06-09 2007-05-23 Leptomycin derivatives MEP88208A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06290948A EP1864682A1 (fr) 2006-06-09 2006-06-09 Dérivés de la Leptomycine
PCT/IB2007/001328 WO2007144709A2 (fr) 2006-06-09 2007-05-23 DÉRIVÉS de LEPTOMYCINE

Publications (1)

Publication Number Publication Date
MEP88208A true MEP88208A (en) 2011-12-20

Family

ID=37311892

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-882/08A MEP88208A (en) 2006-06-09 2007-05-23 Leptomycin derivatives

Country Status (28)

Country Link
US (2) US7816543B2 (fr)
EP (3) EP1864682A1 (fr)
JP (1) JP5162581B2 (fr)
KR (1) KR20090018103A (fr)
CN (2) CN101466409B (fr)
AR (1) AR063668A1 (fr)
AU (1) AU2007258896B2 (fr)
BR (1) BRPI0712899A2 (fr)
CA (1) CA2654322A1 (fr)
CL (1) CL2007001648A1 (fr)
CR (1) CR10459A (fr)
EA (1) EA017345B1 (fr)
EC (1) ECSP088936A (fr)
GT (1) GT200800277A (fr)
HN (1) HN2008001788A (fr)
IL (1) IL195419A0 (fr)
MA (1) MA30689B1 (fr)
ME (1) MEP88208A (fr)
MX (1) MX2008015728A (fr)
MY (1) MY148231A (fr)
NO (1) NO20085127L (fr)
NZ (1) NZ572947A (fr)
SG (2) SG174067A1 (fr)
TN (1) TNSN08463A1 (fr)
TW (1) TWI411609B (fr)
UA (1) UA95959C2 (fr)
WO (1) WO2007144709A2 (fr)
ZA (1) ZA200810015B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1864682A1 (fr) * 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
CN101732308B (zh) * 2008-11-17 2011-11-30 中国人民解放军军事医学科学院毒物药物研究所 来普霉素b的新用途及含有它的药物组合物和产品
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
JP6049642B2 (ja) 2011-02-15 2016-12-21 イミュノジェン・インコーポレーテッド 複合体の調製方法
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US20150148411A1 (en) * 2013-11-25 2015-05-28 The Rockefeller University Compositions and methods for diagnosis and therapy of disorders related to alterations of myh9
CA2953371C (fr) * 2014-06-30 2021-08-24 Tarveda Therapeutics, Inc. Conjugues cibles, particules et preparations associees
CA2996902C (fr) 2015-10-02 2020-06-02 Genentech, Inc. Conjugues anticorps-medicaments de pyrrolobenzodiazepine et methodes d'utilisation
JP7057278B2 (ja) 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
US10417364B2 (en) 2017-01-04 2019-09-17 Stmicroelectronics International N.V. Tool to create a reconfigurable interconnect framework
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
WO2019030284A1 (fr) * 2017-08-09 2019-02-14 Helmholtz-Zentrum für Infektionsforschung GmbH Nouveaux dérivés de ratjadone cytotoxiques ciblés et leurs conjugués
US11531873B2 (en) 2020-06-23 2022-12-20 Stmicroelectronics S.R.L. Convolution acceleration with embedded vector decompression
CN115584329B (zh) * 2022-07-11 2026-03-13 湖北省生物农药工程研究中心 一株链霉菌、其代谢产物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792522A (en) 1983-12-12 1988-12-20 Bristol-Myers Company Rigolettone antitumor complex
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4771070A (en) 1984-08-21 1988-09-13 Warner-Lambert Company CL-1957A antibiotic compound
US4764368A (en) 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
AU6368500A (en) * 1999-07-22 2001-02-13 University Of Medicine And Dentistry Of New Jersey Materials and processes for controlled release of thioamide moiety-containing therapeutic agents by linking to thiol-containing polymers
AU2001294511A1 (en) 2000-06-30 2002-01-08 The Regents Of The University Of California New strategy for leukemia therapy
WO2002062396A2 (fr) * 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Delivrance orale et transcompartimentale amelioree d'agents therapeutiques ou diagnostiques
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
KR20120064120A (ko) * 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
WO2006135371A1 (fr) * 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugués à effets adverses systémiques réduits
EP1864682A1 (fr) * 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine

Also Published As

Publication number Publication date
JP2009539820A (ja) 2009-11-19
NO20085127L (no) 2009-01-08
US20090182038A1 (en) 2009-07-16
CN101466409B (zh) 2012-11-21
EA200870615A1 (ru) 2009-04-28
US20110002947A1 (en) 2011-01-06
HK1134240A1 (en) 2010-04-23
EP2540320A1 (fr) 2013-01-02
CN102731611A (zh) 2012-10-17
AR063668A1 (es) 2009-02-11
MX2008015728A (es) 2009-01-09
AU2007258896A1 (en) 2007-12-21
MA30689B1 (fr) 2009-09-01
ECSP088936A (es) 2009-01-30
MY148231A (en) 2013-03-29
UA95959C2 (en) 2011-09-26
ZA200810015B (en) 2010-02-24
TWI411609B (zh) 2013-10-11
BRPI0712899A2 (pt) 2013-01-08
EP1864682A1 (fr) 2007-12-12
US7816543B2 (en) 2010-10-19
NZ572947A (en) 2011-12-22
GT200800277A (es) 2009-06-16
WO2007144709A3 (fr) 2008-06-12
TW200812996A (en) 2008-03-16
CR10459A (es) 2009-01-09
SG174067A1 (en) 2011-09-29
HN2008001788A (es) 2012-08-27
IL195419A0 (en) 2009-08-03
EA017345B1 (ru) 2012-11-30
CN101466409A (zh) 2009-06-24
CA2654322A1 (fr) 2007-12-21
EP2032172A2 (fr) 2009-03-11
EP2032172B1 (fr) 2012-06-06
AU2007258896B2 (en) 2013-01-24
CL2007001648A1 (es) 2008-01-18
TNSN08463A1 (en) 2010-04-14
SG174066A1 (en) 2011-09-29
WO2007144709A2 (fr) 2007-12-21
JP5162581B2 (ja) 2013-03-13
KR20090018103A (ko) 2009-02-19

Similar Documents

Publication Publication Date Title
MEP88208A (en) Leptomycin derivatives
HRP20150828T8 (hr) Kompozicije i postupci in vitro i in vivo ciljanog oslobađanja lijeka u stanicama sisavaca, preko intaktnih mini-stanica izvedenih iz bakterija
EA201290506A1 (ru) Частицы для доставки множества агентов
AR060187A1 (es) Composicion inmunogenica
MX2012004932A (es) Composiciones orales para el tratamiento de la boca seca.
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
IL208937A0 (en) Cell binding agent cytotoxic drug conjugates, compositions comprising the same and uses thereof
MX2009004664A (es) Inmunoglobulinas hibridas con partes moviles.
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
EA201290838A1 (ru) Конъюгаты пирролбензодиазепина направленного действия
NZ600039A (en) Biocompatible biodegradable fumagillin analog conjugates
IL208936A0 (en) Cell binding agent drug conjugates, compositions comprising the same and uses thereof
EP2396070A4 (fr) Délivrance de médicament par bouchons d'hydrogels
ECSP088759A (es) Composiciones farmacéuticas
EP2143446A4 (fr) Gel hybride comprenant un dérivé de l'acide hyaluronique réticulé chimiquement, et composition pharmaceutique l'utilisant
ATE534698T1 (de) Reifenzusammensetzungen und d komponenten mit freifliessenden füllstoffzusammensetzungen
DK2142586T3 (da) Forseglingssammensætning omfattende polythioether
WO2011082038A3 (fr) Compositions de reprogrammation améliorées
BRPI1007230A2 (pt) metodos e composicoes baseadas na proteina da toxina de shiga tipo 2
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
GT200600097A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
EP1968566A4 (fr) Compositions d'acide cis-9,trans-11-linoleique conjugue et d'acide vaccenique et utilisations de celles-ci
IL208567A0 (en) Oligomer-aryloxy-substituted propanamine conjugates, compositions comprising the same and uses thereof
CO6541608A2 (es) Formulación de empaque para evitar la insolubilidad de las composiciones que contienen quitosán
PA8815701A1 (es) Composiciones agrícolas